Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Myers, MA

Andrew G. Myers, Boston, MA US

Patent application numberDescriptionPublished
20090054665ANALOGS OF SALINOSPORAMIDE A - Disclosed herein are analogs of Salinosporamide A, having the Formula I as follows:02-26-2009
20090093640SYNTHESIS OF ENONE INTERMEDIATE - The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides a more efficient route for preparing the enone intermediate.04-09-2009
20090143581SYNTHESIS OF AVRAINVILLAMIDE, STREPHACIDIN B, AND ANALOGUES THEREOF - The syntheses of the natural products, avrainvillamide and stephacidin B, are provided. The α,β-unsaturated nitrone functionality of avrainvillamide and its 3-alkylidene-3H-indole 1-oxide core is shown to covalently and reversibly bond to heteroatom-based nucleophiles. This capability may allow these molecules to bind active site nucleophiles and may provide the basis for designing potent and selective enzyme inhibitors. Both avrainvillamide and its dimer stephacidin B have been reported to exhibit antiproliferative activity, and avrainvillamide has been reported to exhibit antimicrobial activity against multi-drug resistant bacteria. Avrainvillamide has been found to target cytoskeleton-linking membrane protein (CLIMP-63) thereby preventing cells from undergoing mitosis. The invention provides syntheses of these natural products as well as analogs of these natural products and their functional cores. The compounds of the invention may be used in the treatment of diseases such as cancer, autoimmune diseases, and bacterial infection.06-04-2009
20100130451SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF - The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetra-cycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-pro liferative agents in the treatment of diseases of humans or other animals.05-27-2010
20110009371SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF - The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.01-13-2011
20110009639SYNTHESIS OF ENONE INTERMEDIATE - The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides a more efficient route for preparing the enone intermediate.01-13-2011
20110105515TARGETING THE ONCOPROTEIN NUCLEOPHOSMIN - (+)-Avrainvillamide, a naturally occurring alkaloid with antiproliferative activity, is shown to bind to the oncoprotein nucleophosmin. Nucleophosmin is known to regulate the tumor suppressor protein p53 and is overexpressed in many different human tumors. The invention provides methods of modulating nucleophosmin and p53 using (+)-avrainvillamide and analogues thereof. These compounds may provide leads for the development of novel anti-cancer therapies that target nucleophosmin.05-05-2011
20110166170SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDIN B, AND ANALOGUES THEREOF - The syntheses of the natural products, avrainvillamide and stephacidin B, are provided. The α,β-unsaturated nitrone functionality of avrainvillamide and its 3-alkylidene-3H-indole 1-oxide core is shown to covalently and reversibly bond to heteroatom-based nucleophiles. This capability may allow these molecules to bind active site nucleophiles and may provide the basis for designing potent and selective enzyme inhibitors. Both avrainvillamide and its dimer stephacidin B have been reported to exhibit antiproliferative activity, and avrainvillamide has been reported to exhibit antimicrobial activity against multi-drug resistant bacteria. Avrainvillamide has been found to target cytoskeleton-linking membrane protein (CLIMP-63) thereby preventing cells from undergoing mitosis. The invention provides syntheses of these natural products as well as analogs of these natural products and their functional cores. The compounds of the invention may be used in the treatment of diseases such as cancer, autoimmune diseases, and bacterial infection.07-07-2011
20110190323CORTISTATIN ANALOGUES AND SYNTHESES THEREOF - The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: I and salts thereof, wherein R08-04-2011

Patent applications by Andrew G. Myers, Boston, MA US

Charles Arthur Myers, Medway, MA US

Patent application numberDescriptionPublished
20110203721INTEGRATED SEALING FOR FUEL CELL STACK MANUFACTURING - A seal and corresponding method of manufacture of stacks enabled by the physical properties of the seal are provided. In the instance of a fuel cell or other electrochemical stack, the seal provides low-cost manufacturing and reliable/durable operation in high temperature (e.g., 120° C. to 250° C.) and acidic environments. The seal provides an elastomeric material characteristic providing resiliency and flexibility, and a protective characteristic that protects the seal from the high temperature acidic environment, such as found in high temperature PEM fuel cells. The seal is affixed to a plate of a fuel cell stack assembly prior to assembly of the stack, such that there is no requirement to apply an adhesive seal, gasket, free flow to solid sealing material, or the like, to each plate during assembly of the fuel cell stack, or during a disassembly and re-assembly process.08-25-2011

Cory S. Myers, Westford, MA US

Patent application numberDescriptionPublished
20090041096EFFICIENT SYNCHRONIZATION OF A SPREAD SPECTRUM SIGNAL IN THE PRESENCE OF DELAY AND FREQUENCY UNCERTAINTY - Implementations for the synchronization of a spread spectrum signal in the presence of delay and frequency uncertainty. According to one embodiment, there is a signal processing technique that combines coherent integration with a Fast Fourier Transform (FFT). Coherent integration with the direct sequence code is achieved through the use of shift registers, code modulators, and integrators, and applied to subsequences of the spreading code. Subsequences can then be combined via an FFT to achieve further coherent integration and to simultaneously deal with frequency uncertainty.02-12-2009
20100302086COMPRESSIVE SENSOR ARRAY SYSTEM AND METHOD - A compressive sensor array (CSA) system and method uses compressive sampling techniques to acquire sensor data from an array of sensors without independently sampling each of the sensor signals. In general, the CSA system and method uses the compressive sampling techniques to combine the analog sensor signals from the array of sensors into a composite sensor signal and to sample the composite sensor signal at a sub-Nyquist sampling rate. At least one embodiment of the CSA system and method allows a single analog-to-digital converter (ADC) and single RF demodulation chain to be used for an arbitrary number of sensors, thereby providing scalability and eliminating redundant data acquisition hardware. By reducing the number of samples, the CSA system and method also facilitates the processing, storage and transmission of the sensor data.12-02-2010

John A. Myers, Seattle, MA US

Patent application numberDescriptionPublished
20080249369Compact scanning fiber device - Scanning fiber devices are disclosed. In one aspect, a scanning fiber device may include an actuator tube. The scanning fiber device may also include a cantilevered free end portion of an optical fiber. The cantilevered free end portion of the optical fiber may have an attached end that is coupled with the actuator tube. The cantilevered free end portion of the optical fiber may also have a free end to be moved by the actuator tube. At least a portion of a length of the cantilevered free end portion of the optical fiber may be disposed within the actuator tube. Methods of using scanning fiber devices are also disclosed.10-09-2008

Paul S. Myers, Cambridge, MA US

Patent application numberDescriptionPublished
20100062487Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses - The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.03-11-2010

Paul S. Myers, Jamaica Plain, MA US

Patent application numberDescriptionPublished
20080213778Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses - The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.09-04-2008
20090136959Novel genes encoding proteins having prognostic, diagnostic preventive, therapeutic, and other uses - The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.05-28-2009
20110065124Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses - The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.03-17-2011

Patent applications by Paul S. Myers, Jamaica Plain, MA US

Randall Todd Myers, Pittsfield, MA US

Patent application numberDescriptionPublished
20090163609LOW DENSITY AND HIGH DENSITY POLYETHERIMIDE FOAM MATERIALS AND ARTICLES INCLUDING THE SAME - Polyetherimide foam materials, articles that include these foam materials and methods of making these foam materials and articles. The foam extrusion process uses selected blowing agents, equipment design and processing conditions to produce continuously extruded foam with a substantially uniform cell size in a lower density PEI foam, such as 25 to 50 g/L or a higher density PEI foam, such as 120 to 300 g/L. Due to the greater densities that can be produced as well as the characteristics inherent in polyetherimide articles, the resulting foam materials are suitable for a much broader range of applications.06-25-2009
20090163610CONTINUOUS PROCESS FOR MAKING POLYETHERIMIDE FOAM MATERIALS AND ARTICLES MADE THEREFROM - A continuous process of making polyetherimide foam materials and articles that include these foam materials. The continuous process is a foam extrusion process that uses selected blowing agents, equipment design and processing conditions to continuously produce extruded foam with a substantially uniform cell size in a wide range of cell densities. Subsequent heating may be used in certain embodiments to remove any residual components from the foam, such as any blowing agents or nucleating agents. Due to the greater densities as well as the characteristics inherent in polyetherimide articles, the resulting foam materials are suitable for a much broader range of applications. The continuous process provides a more cost effective product while also avoiding the use of Freon and/or other agents potentially harmful to the environment.06-25-2009

Patent applications by Randall Todd Myers, Pittsfield, MA US

Rene Myers, Framingham, MA US

Patent application numberDescriptionPublished
20110045514METHODS FOR DETECTING MAJOR ADVERSE CARDIOVASCULAR AND CEREBROVASCULAR EVENTS - The present teachings relate to a method of assessing the probability of a major adverse cardiovascular or cerebrovascular event in a human. The method can include measuring a concentration, in a blood-based sample of a human, of a set of analytes, for example, alpha-fetoprotein, cancer antigen 125, glutathione S-transferase, and tissue factor. The method also can include determining a MACCE index for the set of analytes and identifying the human as having an increased likelihood of a major adverse cardiovascular or cerebrovascular event if the MACCE index is greater than zero, or a decreased likelihood of a major adverse cardiovascular or cerebrovascular event if the MACCE index is less than or equal to zero.02-24-2011

Stewart Myers, Lexington, MA US

Patent application numberDescriptionPublished
20080270322DERIVING A PROBABILITY DISTRIBUTION OF A VALUE OF AN ASSET AT A FUTURE TIME - Data are received that represents current prices of options on a given asset. An estimate is derived from the data of a corresponding implied probability distribution of the price of the asset at a future time. Information about the probability distribution is made available within a time frame that is useful to investors, for example, promptly after the current option price information becomes available.10-30-2008